Ehrlich Christopher B 4
4 · CERO THERAPEUTICS HOLDINGS, INC. · Filed Oct 2, 2024
Insider Transaction Report
Form 4
Ehrlich Christopher B
DirectorChairman and CEO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-09-30−572,182→ 0 totalExercise: $1.77Exp: 2034-03-24→ Common Stock (572,182 underlying) - Exercise/Conversion
Common Stock
2024-09-25+5,312,983→ 5,791,808 total - Exercise/Conversion
Series A Convertible Preferred Stock
2024-09-25$1000.00/sh−275$275,000→ 0 total→ Common Stock (5,312,983 underlying)
Holdings
- 3,600(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date.
- [F2]Represents the forfeiture of employee stock options in connection with the Reporting Person's appointment as Chief Executive Officer of the Issuer.